Table 2.
Eradication rate (ER) of the most common treatment regimens in relation to antibiotic susceptibility in treatment naïve patients (group A) and patients after failed therapy (group B)
| Susceptibility sub-groups/common treatments | All subgroups ER% (n/N) |
MET-S/CLA-S ER% (n/N) |
MET-S/CLA-R ER% (n/N) |
MET-R/CLA-S ER% (n/N) |
MET-R/CLA-R ER% (n/N) |
|---|---|---|---|---|---|
| Group A (treatment naïve patients) | |||||
| Tailored triple therapy (TTT) including PAC and PAM | 90% (452/503) | 92% (279/302) | 86% (94/109) | 84% (68/81) | 100% (11/11) |
| PPI + AMO + CLA (PAC) | 88% (252/285) | 91% (185/203) | 0% (0/2) | 83% (65/78) | 100% (2/2) |
| PPI + AMO + MET (PAM) | 92% (200/218) | 95% (94/99) | 88% (94/107) | 100% (3/3) | 100% (9/9) |
| PPI + AMO + CLA + MET sequential | 82% (50/61) | 86% (44/51) | 56% (5/9) | 100% (1/1) | N.A |
| Group B (patients after failed therapy) | |||||
| Tailored triple therapy (TTT) including PAC and PAM | 59% (41/69) | 65% (22/34) | 71% (15/21) | 30% (3/10) | 25% (1/4) |
| PPI + AMO + CLA (PAC) | 52% (14/27) | 60% (12/20) | N.A | 29% (2/7) | N.A |
| PPI + AMO + MET (PAM) | 64% (27/42) | 71% (10/14) | 71% (15/21) | 33% (1/3) | 25% (1/4) |
| PPI + AMO + other antibiotic(s) | 69% (9/13) | N.A | 100% (2/2) | 100% (1/1) | 60% (6/10) |
| Bismuth-based therapy (BMT) | 83% (10/12) | N.A | N.A | 100% (2/2) | 80% (8/10) |
Data are based on all available susceptibility test results for metronidazole (MET) and clarithromycin (CLA)
ER% represents eradication rate (ER) in per cent (%) as the proportion of all patients treated successfully with a confirmed negative test after completed treatment (n) relative to all patients treated (N)
Abbreviation: TTT tailored triple therapy, ER eradication rate, PPI proton pump inhibitor, AMO amoxicillin, CLA clarithromycin, MET metronidazole, PAC for treatment regimen with proton pump inhibitor, amoxicillin, clarithromycin, PAM for treatment regimen with proton pump inhibitor, amoxicillin, metronidazole, BMT bismuth-based therapy, N.A. not applicable
MET-S/CLA-S: Strains susceptible to both metronidazole and clarithromycin. MET-S/CLA-R: Strains susceptible to metronidazole but resistant to clarithromycin. MET-R/CLA-S: Strains resistant to metronidazole but susceptible to clarithromycin. MET-R/CLA-R: Strains resistant to both metronidazole and clarithromycin